TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04228302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC5026 oral capsule
Description: 5 sequential cohorts of 8 subjects randomly assigned to receive single ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort).~Oral doses of EC5026 tested in each cohort: 0.5 mg (Cohort 1), 2 mg (Cohort 2), 8 mg (Cohort 3), 16 mg (Cohort 4), and 24 mg (Cohort 5).~A blinded sentinel group of 2 subjects (1 active and 1 placebo) will be dosed at least 2 days before the remaining 6 subjects (5 active and 1 placebo) will receive blinded doses of active study drug or placebo.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 5 sequential cohorts of 8 subjects randomly assigned to receive single ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort)
Study: NCT02497820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin (acetylsalicylic acid) has a marketing approval for use in the EU and is widely available as an over the counter medicine. However it is not being used within its licensed indication and the aspirin (at any dose in this study) will be treated as an investigational medicinal product (IMP).~Tablets will be provided as enteric-coated 100mg or 300mg tablets for oral use. All patients will receive at least some dose of aspirin but blinding to the actual dose will be achieved by the use of 'dummy' tablets using the same excipients as in the active formulation of the aspirin minus the active ingredient.~The aspirin and dummy tablets should be stored at room temperature below 25⁰C in a dry place.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin (acetylsalicylic acid) has a marketing approval for use in the EU and is widely available as an over the counter medicine. However it is not being used within its licensed indication and the aspirin (at any dose in this study) will be treated as an investigational medicinal product (IMP).~Tablets will be provided as enteric-coated 100mg or 300mg tablets for oral use. All patients will receive at least some dose of aspirin but blinding to the actual dose will be achieved by the use of 'dummy' tablets using the same excipients as in the active formulation of the aspirin minus the active ingredient.~The aspirin and dummy tablets should be stored at room temperature below 25⁰C in a dry place.
Study: NCT04088695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video through a web page
Description: Participants will see a video about blood donation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informative text
Description: Participants will see a brief text about blood donation.
Study: NCT01686555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199
Description: Tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet
Study: NCT03120962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone 20mg/day, for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 900mg/day, titrated up to max tolerated dose or 1800mg/day, for 4-12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin 900mg/day, titrated up to max tolerated dose or 1800mg/day, for 4-12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famciclovir
Description: Famciclovir 500mg three-times daily for 7 days
Study: NCT01093690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoclopramide
Description: ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus metoclopramide 20 mg oral four times a day on day 2-5

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus placebo 20 mg oral four times a day on day 2-5
Study: NCT01862614

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Articaine Hydrochloride + Epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buffered Articaine Hydrochloride + Epinephrine
Study: NCT00674258

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: URLC10, TTK and KOC1
Description: Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10-117 peptide(1mg), TTK- peptide(1mg) and KOC1- peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
Study: NCT01588847

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with Bupivacaine hyperbar 0.5 %
Description: Spinal anesthesia with Bupivacaine hyperbar 0.5 %

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane
Description: General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane
Study: NCT03120962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famciclovir
Description: Famciclovir 500mg three-times daily for 7 days
Study: NCT00293267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir potassium
Description: Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo b.i.d. p.o. with optimized background therapy. Treatment period of 48 weeks.
Study: NCT02331862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Add methylprednisolone in addition to the experience antibiotics in children with urinary tract infection to see if the frequency of the renal scar formation could be decreased
Study: NCT00447148

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: 3-dimensional coronary angiography
Description: 3-dimensional coronary angiography
Study: NCT01067170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pneumatic Compression Stockings
Description: Thigh-high pneumatic compression stockings
Study: NCT00483184

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Veldona,
Description: Very low dose oral natural human interferon alpha lozenges

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Veldona,
Description: Very low dose oral natural human interferon alpha lozenges

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Veldona,
Description: Very low dose oral natural human interferon alpha lozenges
Study: NCT01050816

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chondron(autologous chondrocyte) Implantation
Description: * Test drug: Chondron (more than 12 million chondrocytes in 0.4ml, i.e. 1 vial)~* Directions and dosage:~Suspend the cells in the vial sufficiently, and implant them in the defective part, making sure that sufficient amounts are injected.~\*30 subjects participated in this open clinical trial. Those who agreed to participate voluntarily went through screening to confirm the appropriateness for the clinical trial, and then received Gel type CHONDRON (fibrin mixed autologous chondrocytes) transplantation.
Study: NCT02660710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP
Description: maximum of 6-8 cycles of R-CHOP over 18-24 weeks
Study: NCT00248781

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telecommunications system

Intervention type: DEVICE
Group type: OTHER
Intervention: attention control
Description: health education
Study: NCT03978234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 300 UNT
Description: AbobotulinumtoxinA 300 UNT
Study: NCT03078348

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Immunochemical Test (FIT) Kit
Description: Free FIT Kits distributed at study entry.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Immunochemical Test (FIT) Kit
Description: Free FIT Kits distributed at study entry.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Culturally targeted Photo Novella Booklet
Description: Culturally targeted Photo Novella Booklet + culturally targeted reminders. Print materials developed by the Centers for Disease Control and Prevention (CDC)) to provide information about CRC, importance of screening and available screening tests. Timed reminder letters and/or emails intended as a cue to action and as educational boost to facilitate participant screening decision making and screening uptake.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screen for Life Brochure
Description: Screen for Life Brochure + standard reminders. Print materials developed by the Centers for Disease Control and Prevention (CDC)) to provide information about CRC, importance of screening and available screening tests. Timed reminder letters and/or emails intended as a cue to action and as educational boost to facilitate participant screening decision making and screening uptake.
Study: NCT02816151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: full dose at 16 UI/kg for Dysport or 6,5 UA/kg for Botox
Description: Intradetrusor injection under general anesthesia. Injection done through 25 points of 1cc each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: half dose at 8 UI/kg for Dysport or 3,25 UA/kg for Botox
Description: Intradetrusor injection under general anesthesia. Injection done through 25 points of 1cc each.
Study: NCT01970462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin prior to hospital discharge and 6 weeks following discharge.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients are reandomized to Sitagliptin or placebo for 6 weeks post-operatively
Study: NCT01627327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone furoate/vilanterol 100/25mcg
Description: inhalation powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium bromide 18mcg
Description: inhalation powder
Study: NCT04538326

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Participants performed stepping movements that were either cued by the investigator or interacted with a video game. There were three video game exercises that all involved stepping in either a repeated or a random pattern that was either self-paced or game paced.
Study: NCT04003168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human BCMA targeted T Cells Injection
Description: Autologous genetically modified anti-BCMA CAR transduced T cells
Study: NCT05450315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stride to Survive:An Exercise Guide for Young Adult Cancer Survivors

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Canadian Physical Activity Guidelines
Study: NCT03094780

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Quality of life counseling
Description: Will receive quality of life counseling from PI, social workers, and physical therapists

Intervention type: OTHER
Group type: OTHER
Intervention: Video-conference quality of life counseling
Description: Participants may video-conference to other sites to participate in group session dependent on Florida, Northfield and Arizona enrollment
Study: NCT01175850

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon (DCB)
Description: balloon dilatation and provisional stenting with IN.PACT DCB

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTA Balloon: Balloon Angioplasty
Description: balloon dilatation and provisional stenting with standard non-coated PTA balloon
Study: NCT04020341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Gepotidacin will be available as tablets containing 750 mg gepotidacin. Each dose should be taken with water after consumption of food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching nitrofurantoin
Description: Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Each dose should be taken with water after consumption of food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin
Description: Nitrofurantoin will be available as over-encapsulated capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Each dose should be taken with water after consumption of food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching gepotidacin
Description: Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Each dose should be taken with water after consumption of food.
Study: NCT03036358

Intervention type: OTHER
Group type: OTHER
Intervention: teledermatology consult
Description: Information from the dermatologic assessment will be entered into the patients chart.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine Care
Description: The dermatologic assessment will occur but not added to the patients medical record. Dermatology may still be consulted but will be at the prerogative of the treating hospitalist.
Study: NCT01841346

Intervention type: PROCEDURE
Intervention: Procedure: PCI
Study: NCT02077179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIP Program
Description: The entirety of the HIP Program is delivered through an interactive mobile website.~The physical activity portion of the program consists of daily step counting, prescribed aerobic activity, structured strength and toning workouts, and daily stretching. The program was designed by a local trainer, specializing in postnatal exercise, to increase gradually in intensity, while encouraging a more active lifestyle. The program is designed to be completed at home with minimal equipment.~The nutrition portion of the program consists of 16 video tutorials developed by a local Registered Dietitian and weekly diet logs. The video tutorials cover all aspects of healthy eating, from the basics of Canada's Food Guide, to smart snacking, to eating healthy over the holidays.
Study: NCT03339323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: TKA patients do the exercise intervention
Study: NCT02351219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Study: NCT04528069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACRYSOF® IQ PanOptix® Toric Trifocal IOL
Description: Single-piece, ultraviolet and blue-light filtering, foldable, multifocal toric IOL intended to provide vision to aphakic subjects at near, intermediate, and distance and to correct pre-existing corneal astigmatism. This device is approved in Australia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Cataract extraction by phacoemulsification, followed by implantation of the IOL per investigator's standard of care and instructions for use
Study: NCT04329754

Intervention type: DEVICE
Group type: OTHER
Intervention: Cataract surgery
Description: Cataract surgery with implantation of an intraocular lens (IOL)

Intervention type: DEVICE
Group type: OTHER
Intervention: Cataract surgery
Description: Cataract surgery with implantation of an intraocular lens (IOL)
Study: NCT03584932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LINK2 Youth Services Navigation Intervention
Description: There will be 6 in-person sessions delivered by a youth services navigator, plus weekly check-in calls after session 2 for a total of six months. As part of the learning sessions, the participant will learn important information about HIV and how to get the most out of his/her HIV care.
Study: NCT01137474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Oral tablets administered as 2.5, 5, or 10 mg, once daily for up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Oral tablets administered as 2.5, 5, or 10 mg, once daily for up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Oral tablets administered as 2.5, 5, or 10 mg, once daily for up to 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-matching dapagliflozin
Description: Oral tablets administered as 0 mg once daily for up to 12 weeks
Study: NCT02872701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTL38 for Injection
Description: Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near infrared camera imaging system
Description: Near infrared camera imaging system

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic or Thoracic Surgery
Description: Endoscopic or Thoracic Surgery
Study: NCT01616901

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spontaneous breathing trial
Description: 5 spontaneous breathing trial will be tested by the patients in the same order :~* 7 cm H2O continuous positive airway pressure~* T piece~* 7 cmH2O of pressure support~* 0 cmH20 of pressure support~* 7 cm H2O pressure support ventilation with 7 cmH20 of end expiratory pressure.
Study: NCT01416870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICI176,334-1
Description: Subject will receive single dose of ICI176,334-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICI176,334-1
Description: Subject will receive single dose of ICI176,334-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casodex 80 mg tablet
Description: Subject will receive single dose of Casodex 80 mg tablet
Study: NCT00253968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplivanserin
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration
Study: NCT03963674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diacutaneous fibrolysis
Description: Diacutaneous fibrolysis over the gastrocnemious muscles
Study: NCT00722891

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Purevision Lenses with ReNu Multiplus
Description: Purevision lenses using ReNu Multiplus lens solution for 28 days

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Purevision Lenses with Optifree RepleniSH
Description: Purevision lenses using Optifree RepleniSH lens solution for 28 days
Study: NCT00446381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macugen (pegaptanib)
Description: Pegaptanib 0.3 mg by intravitreal injection once pre-operatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macugen (Pegaptanib)
Description: Pegaptanib 0.3 mg by intravitreal injection once pre-operatively.
Study: NCT03854968

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality control
Description: The performance of the home mechanical ventilator of all patients in the study will be evaluated with a portable device
Study: NCT02645981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Control
Study: NCT00586911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cystadane
Description: Betaine 20 mg a day or identical placebo for 1 year.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Identical Placebo
Description: Placebo
Study: NCT00447980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-501
Description: High Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-501
Description: Low Dose
Study: NCT04052204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avelumab
Description: Investigational fully human anti-PD-L1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avelumab
Description: Investigational fully human anti-PD-L1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avelumab
Description: Investigational fully human anti-PD-L1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bempegaldesleukin
Description: Investigational CD122-biased cytokine agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bempegaldesleukin
Description: Investigational CD122-biased cytokine agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bempegaldesleukin
Description: Investigational CD122-biased cytokine agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talazoparib
Description: poly (adenosine diphosphate \[ADP\] ribose) polymerase (PARP) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: androgen receptor inhibitor
Study: NCT03540654

Intervention type: OTHER
Intervention: Budget impact
Description: Budget impact, using a probabilistic markov model, of discontinuing TKI treatment in patients with CML in deep molecular response since at least two years, compared with current practice (treatment during entire life), from the healthcare system point of view
Study: NCT03220490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5 minute interval between regular glaucoma drops - Long term
Description: In the selected eye, the patient will be asked to take his two regular IOP reduction drugs while keeping a five minute time interval between instillation of the first and second drug for a duration of one month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5 minute interval between regular glaucoma drops - Long term
Description: In the selected eye, the patient will be asked to take his two regular IOP reduction drugs while keeping a five minute time interval between instillation of the first and second drug for a duration of one month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: no interval between regular glaucoma drops - Long term
Description: In the selected eye, the patient will be asked to take his two regular IOP reduction drugs one after the other with no waiting period for a duration of one month.
Study: NCT01683253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/Carbidopa(200mg/50mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopaminergic Agonists
Description: Treated for at least 6 months after diagnosis of Parkinson's Disease.
Study: NCT03043274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: Cangrelor 30 mcg/kg bolus followed by a 4 mcg/kg/min intravenous infusion prior to PCI will be given. It will be continued for ≥ 2 hours or for the duration of the procedure, whichever is longer.